Progenics Pharma (PGNX) Misses Q1 EPS by 4c, Miss on Revenues

Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.23), $0.04 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.35 million versus the consensus estimate of $4.49 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Stardust Power (SDST) Tops Q2 EPS by 1c